WO2012174158A3 - Administration of benzodiazepine - Google Patents

Administration of benzodiazepine Download PDF

Info

Publication number
WO2012174158A3
WO2012174158A3 PCT/US2012/042311 US2012042311W WO2012174158A3 WO 2012174158 A3 WO2012174158 A3 WO 2012174158A3 US 2012042311 W US2012042311 W US 2012042311W WO 2012174158 A3 WO2012174158 A3 WO 2012174158A3
Authority
WO
WIPO (PCT)
Prior art keywords
benzodiazepine
administration
compositions
producing
methods
Prior art date
Application number
PCT/US2012/042311
Other languages
French (fr)
Other versions
WO2012174158A2 (en
Inventor
Steve Cartt
David Medeiros
Garry Thomas Gwozdz
Andrew Loxley
Mark Mitchnick
David Hale
Edward T. Maggio
Original Assignee
Hale Biopharma Ventures, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2012174158(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hale Biopharma Ventures, Llc filed Critical Hale Biopharma Ventures, Llc
Priority to CN201280039077.9A priority Critical patent/CN103796656A/en
Priority to EP12801372.9A priority patent/EP2720699B1/en
Priority to PL18171484T priority patent/PL3415139T3/en
Priority to JP2014515967A priority patent/JP6219272B2/en
Priority to DK12801372.9T priority patent/DK2720699T3/en
Priority to EP22166182.0A priority patent/EP4085899A1/en
Priority to EP18171484.1A priority patent/EP3415139B8/en
Priority to ES12801372.9T priority patent/ES2683902T3/en
Publication of WO2012174158A2 publication Critical patent/WO2012174158A2/en
Publication of WO2012174158A3 publication Critical patent/WO2012174158A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants

Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
PCT/US2012/042311 2011-06-14 2012-06-13 Administration of benzodiazepine WO2012174158A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN201280039077.9A CN103796656A (en) 2011-06-14 2012-06-13 Administration of benzodiazepine
EP12801372.9A EP2720699B1 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine
PL18171484T PL3415139T3 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine
JP2014515967A JP6219272B2 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine composition
DK12801372.9T DK2720699T3 (en) 2011-06-14 2012-06-13 ADMINISTRATION OF BENZODIAZEPINE
EP22166182.0A EP4085899A1 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine
EP18171484.1A EP3415139B8 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine
ES12801372.9T ES2683902T3 (en) 2011-06-14 2012-06-13 Benzodiazepine Administration

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161497017P 2011-06-14 2011-06-14
US61/497,017 2011-06-14
US201161570110P 2011-12-13 2011-12-13
US61/570,110 2011-12-13

Publications (2)

Publication Number Publication Date
WO2012174158A2 WO2012174158A2 (en) 2012-12-20
WO2012174158A3 true WO2012174158A3 (en) 2014-05-01

Family

ID=47357711

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2012/042311 WO2012174158A2 (en) 2011-06-14 2012-06-13 Administration of benzodiazepine

Country Status (10)

Country Link
US (5) US8895546B2 (en)
EP (3) EP2720699B1 (en)
JP (4) JP6219272B2 (en)
CN (2) CN103796656A (en)
DK (2) DK3415139T3 (en)
ES (2) ES2917973T3 (en)
HK (1) HK1250647A1 (en)
PL (1) PL3415139T3 (en)
PT (1) PT3415139T (en)
WO (1) WO2012174158A2 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008112661A2 (en) 2007-03-09 2008-09-18 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
US8530463B2 (en) * 2007-05-07 2013-09-10 Hale Biopharma Ventures Llc Multimodal particulate formulations
WO2008137960A1 (en) * 2007-05-07 2008-11-13 Questor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
ES2586032T3 (en) 2008-03-28 2016-10-11 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
WO2014075135A1 (en) 2012-11-13 2014-05-22 Gordagen Pharmaceuticals Pty Ltd Transmucosal delivery of tocotrienol
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
CA2967287A1 (en) * 2014-11-18 2016-05-26 PixarBio Corporation Compositions for treating acute, post-operative, or chronic pain and methods of using the same
US11077110B2 (en) 2016-03-18 2021-08-03 Tufts Medical Center Compositions and methods for treating and preventing metabolic disorders
JP7312698B2 (en) * 2016-11-18 2023-07-21 オーピアント ファーマシューティカルズ， インコーポレイテッド Compositions and methods for treating opioid overdose
SI3551189T1 (en) 2016-12-09 2024-03-29 Alexza Pharmaceuticals, Inc. Alprazolam for use in treating epilepsy
KR20240036128A (en) * 2017-06-02 2024-03-19 엑스에리스 파머수티클스, 인크. Precipitation resistant small molecule drug formulations
EP3897577A1 (en) * 2018-12-18 2021-10-27 Cipla Limited Intranasal formulation
CN111529489A (en) * 2020-04-17 2020-08-14 山东省药学科学院 Nasal spray containing diazepam
JP2024502466A (en) * 2021-01-08 2024-01-19 ニューレリス、インク． Methods and compositions for rapid delivery of anti-seizure therapeutics
US20230131450A1 (en) * 2021-10-25 2023-04-27 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US20090130216A1 (en) * 2007-05-07 2009-05-21 Hale Biopharma Ventures Multimodal particulate formulations
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
US20090304801A1 (en) * 2005-02-15 2009-12-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine

Family Cites Families (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3109843A (en) 1963-11-05 Process for preparing
US3102116A (en) 1963-08-27 Process for the purification of y-chloeo-
US3371085A (en) 1959-12-10 1968-02-27 Hoffmann La Roche 5-aryl-3h-1,4-benzodiazepin-2(1h)-ones
US3136815A (en) 1959-12-10 1964-06-09 Hoffmann La Roche Amino substituted benzophenone oximes and derivatives thereof
US3340253A (en) 1962-11-28 1967-09-05 Hoffmann La Roche Preparation of certain benzodiazepine compounds
US3243427A (en) 1962-06-21 1966-03-29 Hoffmann La Roche Certain 5-phenyl-1, 2-dihydro (or 1, 2, 4, 5-tetrahydro)-3h-1, 4,-benzodiazepine compounds and their production
US3374225A (en) 1963-03-28 1968-03-19 Hoffmann La Roche Aminobenzodiazepine compounds and methods
NL298071A (en) 1963-06-04
GB1052144A (en) 1964-02-11
US3567710A (en) 1968-06-03 1971-03-02 Hoffmann La Roche Process for the preparation of 1,3-dihydro-2h-1,4-benzodiazepin-2-ones
US3547828A (en) 1968-09-03 1970-12-15 Rohm & Haas Alkyl oligosaccharides and their mixtures with alkyl glucosides and alkanols
US3609145A (en) 1969-01-10 1971-09-28 Upjohn Co 1h-1,4-benzodiazepine-1-sulfonamides
US3987052A (en) 1969-03-17 1976-10-19 The Upjohn Company 6-Phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepines
US3722371A (en) 1970-03-12 1973-03-27 Pneumo Dynamics Corp High ratio linkage mechanism
GB1355998A (en) 1970-09-30 1974-06-12 Unilever Ltd Builders for detergent compositions
US4280957A (en) 1974-09-11 1981-07-28 Hoffmann-La Roche Inc. Imidazodiazepines and processes therefor
JPS57128634A (en) 1981-02-03 1982-08-10 Eisai Co Ltd Elastase-containing compound increasing absorption
US4608278A (en) 1983-06-22 1986-08-26 The Ohio State University Research Foundation Small particule formation and encapsulation
JPS60208911A (en) * 1984-03-28 1985-10-21 Green Cross Corp:The Diazepam preparation for rectal infusion
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
JPS61267528A (en) * 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd Transnasal calcitonin agent containing absorbefacient
DE3444958A1 (en) 1984-12-10 1986-06-12 Henkel KGaA, 4000 Düsseldorf USE OF ALKYL GLYCOSIDES AS A POTENTIZING AGENT IN ANTISEPTIC AGENTS AND DISINFECTANT AND CLEANING AGENTS WITH AN INCREASED BACTERICIDAL EFFECT
DK17685D0 (en) 1985-01-14 1985-01-14 Hans Goeran Magnusson glycoside
US5192528A (en) 1985-05-22 1993-03-09 Liposome Technology, Inc. Corticosteroid inhalation treatment method
CA1338736C (en) 1986-12-05 1996-11-26 Roger Baurain Microcrystals containing an active ingredient with affinity for phospholipids and at least one phospholipid; process for preparing the same
FR2608988B1 (en) 1986-12-31 1991-01-11 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES
US5550220A (en) 1987-05-13 1996-08-27 Curtice-Burns, Inc. Alkyl glycoside fatty acid polyester fat substitute food compositions and process to produce the same
US4921838A (en) 1987-06-16 1990-05-01 Trustees Of Boston University Angiogenic and blood perfusion inducing properties of amphiphilic compounds
JPH01151528A (en) 1987-12-08 1989-06-14 Taiho Yakuhin Kogyo Kk Transmucous absorbefacient
JPH076254Y2 (en) 1988-03-31 1995-02-15 株式会社淀川製鋼所 Structure mounting structure and roof mounting structure using split horizontal members
KR900701310A (en) 1988-11-14 1990-12-01 오스카 아끼히꼬 Interferon nonadministration preparation
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
US5705363A (en) 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
FR2651680B1 (en) 1989-09-14 1991-12-27 Medgenix Group Sa NOVEL PROCESS FOR THE PREPARATION OF LIPID MICROPARTICLES.
US5188837A (en) 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5369095A (en) 1990-02-14 1994-11-29 Alcon Laboratories, Inc. Compositions and method comprising substituted glycosides as mucus membrane permeation enhancers
US5091188A (en) 1990-04-26 1992-02-25 Haynes Duncan H Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs
ATE164080T1 (en) * 1990-05-10 1998-04-15 Bechgaard Int Res PHARMACEUTICAL PREPARATION CONTAINING N-GLYCOFUROLES AND N-ETHYLENE GLYCOLS
US5252318A (en) 1990-06-15 1993-10-12 Allergan, Inc. Reversible gelation compositions and methods of use
CA2065265A1 (en) 1990-06-27 1991-12-28 Tadao Shoji Alkylated oligosaccharides and acetyl derivatives of the same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
ES2095348T3 (en) 1991-05-16 1997-02-16 Kao Corp AQUEOUS ALKYL GLYCOSIDE SOLUTION AGAINST MICROBIAL ACTIVITY.
US5317010A (en) 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment
US5236707A (en) 1991-11-08 1993-08-17 Dallas Biotherapeutics, Inc. Stabilization of human interferon
US5457100A (en) * 1991-12-02 1995-10-10 Daniel; David G. Method for treatment of recurrent paroxysmal neuropsychiatric
US5308531A (en) 1992-08-31 1994-05-03 Henkel Corporation Pine-oil containing hard surface cleaning composition
WO1994005262A1 (en) 1992-09-10 1994-03-17 F.H. Faulding & Co. Limited Sustained release matrix composition
ATE220327T1 (en) 1992-09-29 2002-07-15 Inhale Therapeutic Syst PULMONARY RELEASE OF ACTIVE FRAGMENTS OF THE PARATHORMONE
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
WO1994020116A1 (en) 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5661130A (en) 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
CN1098708C (en) 1993-10-21 2003-01-15 久光制药株式会社 Pernasal composition and pernasal preparation containing the same
GB9409778D0 (en) 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5955425A (en) 1996-08-02 1999-09-21 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
SE9403846D0 (en) 1994-11-09 1994-11-09 Univ Ohio State Res Found Small particle formation
SE9404196D0 (en) 1994-12-02 1994-12-02 Astra Ab New antithrombotic formulation
PL320856A1 (en) 1994-12-22 1997-11-10 Astra Ab Aerosol drug preparations
SE9404468D0 (en) 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5716642A (en) 1995-01-10 1998-02-10 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
US5665331A (en) 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5662883A (en) 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
PT821671E (en) 1995-04-20 2001-04-30 Pfizer ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES AS MMP AND TNF INHIBITORS
US20030118594A1 (en) 1995-06-07 2003-06-26 Bishwajit Nag Stable formulations of mhc-peptide complexes
US6143211A (en) 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
EP0855906B1 (en) 1995-10-17 2008-02-20 Jagotec AG Insoluble drug delivery
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
DE69624081T2 (en) 1995-12-20 2003-06-12 Hoffmann La Roche Matrix metalloprotease inhibitors
US6254854B1 (en) 1996-05-24 2001-07-03 The Penn Research Foundation Porous particles for deep lung delivery
JP2000513374A (en) 1996-07-01 2000-10-10 ファルマシア・アンド・アップジョン・カンパニー Method for producing 8-chloro-6- (2-fluorophenyl) -1-methyl-4H-imidazo [1,5-A] benzodiazepine
EP0818442A3 (en) 1996-07-12 1998-12-30 Pfizer Inc. Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
WO1998003516A1 (en) 1996-07-18 1998-01-29 Pfizer Inc. Phosphinate based inhibitors of matrix metalloproteases
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
EP0950059B1 (en) 1997-01-06 2004-08-04 Pfizer Inc. Cyclic sulfone derivatives
ES2202796T3 (en) 1997-02-03 2004-04-01 Pfizer Products Inc. DERIVATIVES OF ARILSULFONYLAMINOHYDROXAMIC ACIDS.
CA2280099C (en) 1997-02-05 2005-12-27 Jago Pharma Ag Medical aerosol formulations
EP0966438A1 (en) 1997-02-07 1999-12-29 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
JP3710489B2 (en) 1997-02-11 2005-10-26 ファイザー・インク Arylsulfonylhydroxamic acid derivatives
US20050004049A1 (en) 1997-03-11 2005-01-06 Elan Pharma International Limited Novel griseofulvin compositions
US6245760B1 (en) 1997-05-28 2001-06-12 Aventis Pharmaceuticals Products, Inc Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
EP1012331B1 (en) 1997-07-01 2006-03-29 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
UA61963C2 (en) 1997-08-08 2003-12-15 Pfizer Prod Inc Aryloxysulfonylaminohydroxamic acid derivatives
US6165484A (en) 1997-08-26 2000-12-26 Wake Forest University EDTA and other chelators with or without antifungal antimicrobial agents for the prevention and treatment of fungal infections
US20040141923A1 (en) 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
MY120063A (en) 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
AU716724B2 (en) 1998-03-26 2000-03-02 Morton International, Inc. A latent mercaptan as a heat stabilizer
PA8469401A1 (en) 1998-04-10 2000-05-24 Pfizer Prod Inc BICYCLE DERIVATIVES OF HYDROXAMIC ACID
PA8469501A1 (en) 1998-04-10 2000-09-29 Pfizer Prod Inc HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO
TWI223598B (en) 1998-06-22 2004-11-11 Pfizer Ireland Pharmaceuticals An intranasal pharmaceutical composition for the treatment of male erectile dysfunction or female sexual disorders, an intranasal delivery system or device and sildenafil mesylate
ITMI981528A1 (en) 1998-07-03 2000-01-03 Recordati Ind Chimica E Farma TOPICAL FORMULATIONS OF ACICLOVIR
EP1117384A1 (en) 1998-10-01 2001-07-25 Elan Pharma International Limited Controlled release nanoparticulate compositions
US6114361A (en) 1998-11-05 2000-09-05 Pfizer Inc. 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US20030087820A1 (en) 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
US6495498B2 (en) 1999-05-27 2002-12-17 Johnson & Johnson Consumer Companies, Inc. Detergent compositions with enhanced depositing, conditioning and softness capabilities
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB9912961D0 (en) 1999-06-03 1999-08-04 Pfizer Ltd Metalloprotease inhibitors
CA2379365C (en) 1999-07-26 2009-11-17 Sk Corporation Transnasal anticonvulsive compositions and modulated process
US7144574B2 (en) 1999-08-27 2006-12-05 Maxygen Aps Interferon β variants and conjugates
US6316410B1 (en) 1999-09-22 2001-11-13 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
CN1303674A (en) * 1999-12-02 2001-07-18 山东省医药工业研究所 Alprazolam nasal spray
IL150109A0 (en) 1999-12-09 2002-12-01 Chiron Corp Method for administering a cytokine to the central nervous system and the lymphatic system
WO2001051030A1 (en) 2000-01-10 2001-07-19 Dura Pharmaceuticals, Inc. Pharmaceutical formulation and method for pulmonary and oral delivery
US20030118547A1 (en) 2000-01-27 2003-06-26 Vandenberg Grant William Composition for intestinal delivery
US7171965B2 (en) 2000-02-01 2007-02-06 Valois S.A.S. Breath actuated dry powder inhaler and tape dose strip
US6610271B2 (en) 2000-05-10 2003-08-26 University Of Kentucky Research Foundation System and method for intranasal administration of lorazepam
US6316029B1 (en) 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US20030181411A1 (en) 2002-03-20 2003-09-25 Elan Pharma International Ltd. Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
US20040147473A1 (en) 2000-11-10 2004-07-29 Warrell Raymond P. Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
US6595210B2 (en) 2000-11-27 2003-07-22 Unisia Jecs Corporation Inhalator for administering powder composition
AU3664102A (en) 2000-12-01 2002-06-11 Battelle Memorial Institute Method for stabilizing biomolecules in liquid formulations
US6869617B2 (en) 2000-12-22 2005-03-22 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US6884436B2 (en) 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
GB0102902D0 (en) 2001-02-06 2001-03-21 Innovata Biomed Ltd Medicaments
US20040176359A1 (en) 2001-02-20 2004-09-09 University Of Kentucky Research Foundation Intranasal Benzodiazepine compositions
US7316819B2 (en) 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
US6884768B2 (en) 2001-06-14 2005-04-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
GB0116107D0 (en) * 2001-06-30 2001-08-22 West Pharm Serv Drug Res Ltd Pharmaceutical composition
JP2005508939A (en) 2001-10-12 2005-04-07 エラン ファーマ インターナショナル，リミティド Composition having combined immediate release and sustained release characteristics
FR2834212B1 (en) 2001-12-27 2004-07-09 Besins Int Belgique USE OF IMMEDIATE RELEASE POWDER IN PHARMACEUTICAL AND NUTRACEUTICAL COMPOSITIONS
US20060106227A1 (en) 2002-06-13 2006-05-18 Dr Reddy's Laboratories Limited 3-'2-(Dimethylamino) ethyl!-n-methyl-1h-indole-5-methanesulfonamide and the succinate thereof
CN1688293A (en) 2002-09-16 2005-10-26 韦思公司 Delayed release formulations for oral administration of a polypeptide therapeutic agent and methods of using same
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US20040258663A1 (en) 2003-05-08 2004-12-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of interferon alpha
GB0310919D0 (en) 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
WO2005018565A2 (en) 2003-08-21 2005-03-03 Transoral Pharmaceuticals, Inc. Compositions for delivering 5-ht agonists across the oral mucosa and methods of use thereof
US7879360B2 (en) 2003-11-05 2011-02-01 Elan Pharma International, Ltd. Nanoparticulate compositions having a peptide as a surface stabilizer
DE60322727D1 (en) 2003-12-15 2008-09-18 Phasys Gmbh M Refolded membrane protein in monodisperse form
DE102004017934A1 (en) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg New alkyne compounds having MCH antagonist activity and medicaments containing these compounds
US7877377B2 (en) * 2004-06-03 2011-01-25 International Business Machines Corporation Dropping tautological predicates from SQL queries for reusability
SG173326A1 (en) 2004-06-04 2011-08-29 Camurus Ab Liquid depot formulations
US8268791B2 (en) 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US20090047347A1 (en) 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046969A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20110257096A1 (en) 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US9114069B2 (en) 2004-08-25 2015-08-25 Aegis Therapeutics, Llc Antibacterial compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation Absorption enhancers for drug administration
EP2623095A1 (en) 2004-11-16 2013-08-07 Elan Pharma International Limited Injectable nanoparticulate olanzapine formulations
EP1848403B8 (en) 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
ES2385513T3 (en) 2005-10-11 2012-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Composition for nasal administration
US8911751B2 (en) * 2005-10-11 2014-12-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions for nasal delivery
WO2007059019A2 (en) * 2005-11-14 2007-05-24 Winch Peter D Novel colored solutions of injectable drugs and their pharmaceutically acceptable salts
DE102006027795A1 (en) 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Smoking cessation combination wafer
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
TW200824693A (en) 2006-08-28 2008-06-16 Jazz Pharmaceuticals Inc Pharmaceutical compositions of clonazepam and methods of use thereof
WO2009046444A2 (en) * 2007-10-05 2009-04-09 Mdrna, Inc. Formulation for intranasal administration of diazepam
EP2271214B1 (en) * 2008-03-28 2017-05-03 Particle Sciences, Inc. Pharmaceutical solutions and method for solubilizing therapeutic agents
US8895546B2 (en) 2009-03-27 2014-11-25 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
KR101517415B1 (en) 2008-05-14 2015-05-07 에스케이바이오팜 주식회사 Transnasal anticonvulsive pharmaceutical composition comprising poorly soluble anticonvulsant

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304801A1 (en) * 2005-02-15 2009-12-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
US20080279784A1 (en) * 2007-05-07 2008-11-13 Questcor Pharmaceuticals, Inc. Nasal administration of benzodiazepines
US20090130216A1 (en) * 2007-05-07 2009-05-21 Hale Biopharma Ventures Multimodal particulate formulations
US20090258865A1 (en) * 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions

Also Published As

Publication number Publication date
US9763876B2 (en) 2017-09-19
JP2021130663A (en) 2021-09-09
HK1250647A1 (en) 2019-01-11
WO2012174158A2 (en) 2012-12-20
EP2720699A2 (en) 2014-04-23
JP6523397B2 (en) 2019-05-29
EP4085899A1 (en) 2022-11-09
US20170196884A1 (en) 2017-07-13
EP3415139B1 (en) 2022-04-06
EP3415139A1 (en) 2018-12-19
JP2018039813A (en) 2018-03-15
EP2720699A4 (en) 2015-04-29
US20130065886A1 (en) 2013-03-14
JP6883918B2 (en) 2021-06-09
ES2917973T3 (en) 2022-07-12
CN103796656A (en) 2014-05-14
US20220241187A1 (en) 2022-08-04
US8895546B2 (en) 2014-11-25
EP2720699B1 (en) 2018-05-16
JP2014519525A (en) 2014-08-14
DK2720699T3 (en) 2018-08-20
US20150065491A1 (en) 2015-03-05
US20220117887A1 (en) 2022-04-21
EP3415139B8 (en) 2022-05-18
PT3415139T (en) 2022-06-20
CN107737100A (en) 2018-02-27
DK3415139T3 (en) 2022-06-20
JP6219272B2 (en) 2017-10-25
PL3415139T3 (en) 2022-07-11
JP2019163273A (en) 2019-09-26
ES2683902T3 (en) 2018-09-28

Similar Documents

Publication Publication Date Title
WO2012174158A3 (en) Administration of benzodiazepine
WO2009121039A3 (en) Administration of benzodiazepine compositions
WO2011103202A3 (en) Androgen receptor modulators and uses thereof
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012037411A3 (en) Estrogen receptor modulators and uses thereof
WO2011156518A3 (en) Estrogen receptor modulators and uses thereof
WO2010115552A8 (en) Bispecific anti-erbb-3/anti-c-met antibodies
EA024842B9 (en) Compounds as modulators of pi3k protein kinase
MY194495A (en) Compositions and methods for transmucosal absorption
WO2012021715A3 (en) Stable formulations of linaclotide
WO2013028942A8 (en) Targeting microbubbles
WO2011141685A3 (en) Systemic nasal compositions comprising cocoyl proline or at least one of the constituents thereof
WO2012103810A1 (en) Certain chemical entities, compositions, and methods
MX2014010537A (en) Liver x receptor (lxr) modulators for the treatment of dermal diseases, disorders and conditions.
WO2014066799A3 (en) Modulators of resistant androgen receptor
WO2013134534A3 (en) Solid state forms of cabazitaxel and processes for preparation thereof
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
WO2014137797A3 (en) Stable glucokinase activator compositions
UA116889C2 (en) COMPOSITION COMPRISING A MIXTURE OF CD95-Fc ISOFORMS
PH12014502876A1 (en) Pharmaceutical composition containing fimasartan and hydrochlorothiazide
WO2014007772A3 (en) Inhalation compositions comprising glucose anhydrous
WO2014007781A3 (en) Inhalation compositions
EP2889287A4 (en) Dolastatin-10 derivative, method of producing same and anticancer drug composition containing same
EP3020417A4 (en) Pharmaceutical composition for respiratory administration

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12801372

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2014515967

Country of ref document: JP

Kind code of ref document: A